It's hard enough to find undervalued stocks today, and a stock that is
already up more than 40% over the last year and within a few percentage
points of its 52-week high is not initially the most promising
candidate. To be sure, PRA Health Sciences (NASDAQ:PRAH)
is not conventionally cheap on backward-looking multiples and there are
valid concerns that the CRO market could be in for a harder stretch as
biotech funding dries up and Big Pharma pushes another round of
consolidation. On the other hand, PRA's strong foundation in clinical
trial management and its growing capabilities in strategic outsourcing
and data/analytics shouldn't be ignored, and I believe there are
opportunities here for the company to outgrow its addressed market.
Follow the link for more:
PRA Health Sciences' Special Mix Could Have More To Offer
Showing posts with label Parexel. Show all posts
Showing posts with label Parexel. Show all posts
Thursday, March 16, 2017
PRA Health Sciences' Special Mix Could Have More To Offer
Labels:
LabCorp,
Parexel,
PRA Health Sciences,
Quintiles,
Takeda
Thursday, October 6, 2011
Investopedia: PPD Goes Private
For some time now, investors have been expecting big things from the providers of outsourced pharmaceutical research and clinical services. The thought has always been that as major pharmaceutical companies like Pfizer (NYSE:PFE) and Merck (NYSE:MRK) conduct mass-firings, the industry would evolve more towards a focus on drug target identification and marketing, and would outsource more and more functions like clinical development. That plan has not exactly lived up to investor expectations and Monday's announcement that Pharmaceutical Product Development (NYSE:PPDI) is selling itself to private buyers, looks to be a curious deal.
The Deal
PPD announced that it had accepted a $3.9 billion all-cash offer from Carlyle and Hellman & Friedman. At a price of $33.25 per share, PPD shareholders are getting a 30% premium to Friday's close and a fairly sizable premium to other major CROs like Covance (NYSE:CVD) and Parexel (Nasdaq:PRXL). By the same token, though, this deal is coming in at the lower end of the range of the company's fair value and shareholders who remember when this stock traded in the $40 range, may not be so thrilled with this deal.
To read more, click below:
http://stocks.investopedia. com/stock-analysis/2011/PPD- Goes-Private-PPDI-CVD-PRXL- CRL-ICLR-ERT-PFE-MRK1005.aspx
The Deal
PPD announced that it had accepted a $3.9 billion all-cash offer from Carlyle and Hellman & Friedman. At a price of $33.25 per share, PPD shareholders are getting a 30% premium to Friday's close and a fairly sizable premium to other major CROs like Covance (NYSE:CVD) and Parexel (Nasdaq:PRXL). By the same token, though, this deal is coming in at the lower end of the range of the company's fair value and shareholders who remember when this stock traded in the $40 range, may not be so thrilled with this deal.
To read more, click below:
http://stocks.investopedia.
Tuesday, July 6, 2010
CRO's A-OK
Most academics and analysts consider increasing specialization a sign of maturity and efficiency within an industry. Luminaries like Henry Ford and Steve Jobs may have had visions of controlling every part of the manufacturing process, but more and more companies take the approach of focusing on a narrow part of the process and outsourcing everything else.
Enter the CRO
The pharmaceutical and biotechnology industry is no different. While most companies do maintain in-house R&D capabilities, more and more they look to outside firms for critical steps in the process. One of the biggest industries to spring up to serve the pharma sector is contract research organizations (CROs). CROs help firms research new compounds, optimize lead candidate identification, conduct early-stage testing and facilitate the late-stage clinical trials that the FDA requires for approval.
There are now believed to be more than 1,000 CROs worldwide, and this sector captured about 20% of the global bio-pharma research budget in 2008. Given the exceptional costs of conducting clinical trials, as well as the complexity and intricacy of patient management and data analysis, it is fair to assume this percentage is going to increase. Simply put, bio-pharma companies are skilled at developing compounds and (particularly in the case of big pharma) marketing them, and conducting their own trials is a hassle that many organizations have learned they just do not need. (For more see, Measuring The Medicine Makers.)
For the complete article, please continue on to:
http://stocks.investopedia. com/stock-analysis/2010/ Playing-Big-Pharma-With-CROs- CRL-PRXL-PPDI-MRK-KNDL-CVD- ICLR0706.aspx
The original article indicated that ICON is a British company. This is incorrect. ICON is headquartered in Ireland. The piece will be corrected.
Enter the CRO
The pharmaceutical and biotechnology industry is no different. While most companies do maintain in-house R&D capabilities, more and more they look to outside firms for critical steps in the process. One of the biggest industries to spring up to serve the pharma sector is contract research organizations (CROs). CROs help firms research new compounds, optimize lead candidate identification, conduct early-stage testing and facilitate the late-stage clinical trials that the FDA requires for approval.
There are now believed to be more than 1,000 CROs worldwide, and this sector captured about 20% of the global bio-pharma research budget in 2008. Given the exceptional costs of conducting clinical trials, as well as the complexity and intricacy of patient management and data analysis, it is fair to assume this percentage is going to increase. Simply put, bio-pharma companies are skilled at developing compounds and (particularly in the case of big pharma) marketing them, and conducting their own trials is a hassle that many organizations have learned they just do not need. (For more see, Measuring The Medicine Makers.)
For the complete article, please continue on to:
http://stocks.investopedia.
The original article indicated that ICON is a British company. This is incorrect. ICON is headquartered in Ireland. The piece will be corrected.
Thursday, May 13, 2010
Will Adaptive Design Change the BioPharma World?
I wrote the following for Investopedia, and it was published today.
I'm actually pretty interested in seeing what, if any, reaction I get to this. I really do believe this is one of the bigger ideas that could emerge in biopharma over the next few years, but it is an idea that you scarcely hear about outside of occasional panels and forums at industry conferences and meetings.
I hope you find it interesting.
Every so often a good idea comes out way ahead of its time. Fuel cells actually predate the gasoline engine, the Apple (Nasdaq:AAPL)Newton is the almost-forgotten iPad/iPhone predecessor, and Nikola Tesla sketched out plans for concepts like wireless energy transfer and airplanes that could take off vertically in the 1920s.
Adaptive clinical trial design may ultimately belong on this list as well. Although the idea of changing pharmaceutical drug trials in response to data generated within the trial has been around for at least 10 years, the idea may finally be on the cusp of being realized. Should this concept become more commonplace, it could be a major step forward for biotechnology and pharmaceutical companies.
Read the full column at:
http://stocks.investopedia.com/stock-analysis/2010/Will-Adaptive-Design-Change-The-BioPharma-World-AMGN-GILD-ITMN-EXEL-LLY-PFE-PRXL0513.aspx
I'm actually pretty interested in seeing what, if any, reaction I get to this. I really do believe this is one of the bigger ideas that could emerge in biopharma over the next few years, but it is an idea that you scarcely hear about outside of occasional panels and forums at industry conferences and meetings.
I hope you find it interesting.
Every so often a good idea comes out way ahead of its time. Fuel cells actually predate the gasoline engine, the Apple (Nasdaq:AAPL)
Adaptive clinical trial design may ultimately belong on this list as well. Although the idea of changing pharmaceutical drug trials in response to data generated within the trial has been around for at least 10 years, the idea may finally be on the cusp of being realized. Should this concept become more commonplace, it could be a major step forward for biotechnology and pharmaceutical companies.
Read the full column at:
http://stocks.investopedia.com/stock-analysis/2010/Will-Adaptive-Design-Change-The-BioPharma-World-AMGN-GILD-ITMN-EXEL-LLY-PFE-PRXL0513.aspx
Labels:
Abbott Labs,
adaptive clinical trial,
Amgen,
biotech,
Covance,
Exelixis,
Gilead,
InterMune,
Lilly,
Merck,
Novartis,
Parexel,
Pfizer,
pharmaceuticals
Subscribe to:
Posts (Atom)